A multifunctional nano capsid capable of efficiently delivering therapeutic and diagnostic agents for targeting diverse disease models through multiple routes of administration. Get ready to revolutionize the world of drug delivery. BioCapZ is a groundbreaking nano-delivery system that surpasses all others on the market, including AAV, SV40, liposomes, and polymers. This patented technology can be customized through chemical and genetic engineering to maximize drug delivery efficiency. Invest in BioCapZ now and join us in shaping the future of drug delivery. Furthermore, the viral capsid’s surface can be engineered to allow targeted delivery to specific tissues and present multiple epitopes on the surface for vaccine purposes. With relatively quick production time and cost, BioCapZ provides an easy-to-store nanoplatform using an icosahedral scaffold for a broad range of therapeutic and theranostic applications.
Davis, United States
Founded in 2017
1-10 Employees
Working industry
Other
Type of company
Manufacturer
Locations
1 Headquarter
Specialised areas
Other Support Services, Administrative and Support Services, Administrative and Support and Waste Management and Remediation Services, Business services at non-commercial site
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Astrid Pharma Corp. operates in 1 country around the world
Get an overview of the locations of Astrid Pharma Corp.
Location
Country
State
City
Headquarter
United States
California
Davis
Some frequent questions that have been asked about Astrid Pharma Corp.
Where is Astrid Pharma Corp. located?
The company headquarter of Astrid Pharma Corp. is located in Davis, California, United States. It's worth noting, that the company may have more locations
How many employees does Astrid Pharma Corp. approximately have?
As of the latest available information Astrid Pharma Corp. has around 1-10 employees worldwide.
When was Astrid Pharma Corp. founded?
Astrid Pharma Corp. was founded in 2017
In which industries does Astrid Pharma Corp. mainly work?
The company Astrid Pharma Corp. has it's main focus in the industries of Other
Check out some interesting alternative companies to Astrid Pharma Corp.
capsitec GmbH
Planegg, Germany
1-10 Employees
2021
At capsitec, our mission is to completely change how we approach antiviral therapy. Our mission is to develop this concept into a versatile and adaptable platform for treating viral diseases. Capsitec is dedicated to making this vision a reality by continuously innovating and expanding the applications of our core technology. Capsitec leverages DNA origami nanofabrication, a cutting edge technique in nanotechnology and synthetic biology, to create tailor-made objects that self-assemble from DNA molecules. Capsitec's team has created shells with internal diameters ranging from 30 nm to 400 nm, which can thus accommodate the vast majority of known virus particles inside them. At capsitec, we work on developing this approach into a versatile and adaptable platform for treating viral diseases. Our vision also extends to making more powerful gene delivery vectors and other applications in the future. We are convinced our technology will help addressing the unmet needs of patients and healthcare providers worldwide, contributing to a healthier future.
Capsida
Thousand Oaks, United States
11-50 Employees
2019
Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders. At Capsida, we’re not limited by the way things have always been done. Capsida’s innovation and intellectual property can be broadly applied to all therapeutic areas. The Capsida platform generates capsids optimized to target specific tissue types and limits transduction of tissues and cell types that are not relevant to the disease, allowing for improved efficacy and safety. Capsida’s proprietary technology is used to engineer capsids that can significantly improve targeted tissue penetration, thereby allowing use in both rare and common diseases across all ages – unlike traditional gene therapies aimed at treating rare disorders, usually in infants. Capsida’s CNS programs are delivered through intravenous (IV) administration. Capsida has quickly developed into a fully-integrated gene therapy company. Capsida’s AAV gene therapy platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a Caltech neuroscience professor.
ATOCAP LIMITED
London, United Kingdom
1-10 Employees
2011
AtoCap’s team combines world-class academic, clinical and commercialisation expertise and has a strong track record of successfully translating highly innovative technologies into commercial opportunities that generate substantive income and impact endpoints for stakeholders and investors. Microencapsulation: AtoCap Technology enables the encapsulation of patient-specific combinations of generic drugs such as antibiotics and chemotherapeutics into a multi-layered capsule. Our first product, CapFuran®, enables time-release killing of a variety of patient-derived uropathogenic bacterial species, including E. Targeted and Penetrative Delivery: The capsules can be delivered by a single, minimally invasive outpatient procedure. The capsules can be adapted to deliver multiple other drug cargos to treat a variety of clinical indications.
ImmTune Therapies
Stevenage, United Kingdom
1-10 Employees
2019
We are developing a versatile nanoparticle platform for this purpose, which we can specifically target to cells of choice. We are always open to partnering with companies and institutions with complementary expertise or technologies to facilitate in vivo delivery and speed up clinical development. We are actively seeking collaborations where delivering multiple payloads to specific cells is highly desirable in achieving a particular therapeutic effect. Deliver Biosciences is building a nanoparticle-based delivery platform to genetically engineer cells inside patients to create scalable, affordable and potent cell and gene therapies. Our team includes driven and passionate scientists and experts in cell and molecular biology, chemistry, nanotechnology, and cell/gene therapy from several research institutions including the University of Cambridge, Imperial College London, University College London, Stanford University and King’s College London. Our nanoparticles have been designed to avoid accumulation in off-target organs such as the liver, and to deliver the payloads efficiently to the desired cells in the body. Our first product targets T-cells and delivers a chimeric antigen receptor (CAR) gene, to turn them into tumour killing CAR-T cells. Our product will be easier to administer, will not require specialised manufacturing centres that come with long and expensive supply chains, reaching more patients.
Vector Bioscience Cambridge
Cambridge, United Kingdom
1-10 Employees
-
We are dedicated to transforming oncology treatments with our cargo-agnostic technology. We are providing the ultimate precision medicine, enacting a paradigm change in drug therapy development. Vector Bioscience develops a machine-learning empowered drug delivery platform. Our precision-targeted delivery minimizes side effects with a higher uptake and slow release. By tailoring delivery, we achieve high local concentrations of traditionally difficult-to-formulate therapeutics. Through pioneering tomorrow’s therapies we are building a future where we do not fear cancer. We’re committed to delivering novel treatments to rare disease patients.
Microcaps
Zurich, Switzerland
1-10 Employees
2018
Microcaps emerged from ETH Zurich’s Complex Material Group. Our vision is to redefine the market standards and generate sustainable value with microencapsulated products by providing the world’s first industrial microfluidic platform. At Microcaps, our mission is to revolutionize industries with novel encapsulation solutions. We are committed to providing sustainable value to our customers through our microfluidic platform for industrial applications. It is built on a disruptive microfluidic technology that offers encapsulation solutions for the cosmetic, food, and pharmaceutical sectors. We strive to redefine market standards by delivering innovative, high-quality microencapsulated products that meet the unique needs of cosmetic, food and pharmaceutical industry. Our dedication to excellence drives us to exceed expectations and provide exceptional service to our customers. Revolutionize your cosmetic, nutrition, and pharmaceutical products with the most innovative and effective microencapsulation solution on the market.